Press Releases 2012
Date Title
Nov 30, 2012 Agennix AG Reports Financial Results for Third Quarter and First Nine Months of 2012
Nov 30, 2012 Agennix AG Reports Additional Talactoferrin Alfa Data
Nov 06, 2012 Agennix AG Schedules Conference Call on November 30, 2012 to Discuss Third Quarter 2012 Financial Results
Aug 24, 2012 Agennix AG Announces Corporate Restructuring
Aug 06, 2012 Agennix Reports Results of FORTIS-M Phase III Trial with Talactoferrin Alfa in Non-small Cell Lung Cancer
Jul 31, 2012 Agennix AG Reports Financial Results for Second Quarter and First Half of 2012
Jul 30, 2012 Agennix AG Announces Notice of Allowance for U.S. Patent Application Covering Use of Talactoferrin Alfa to Treat Non-Small Cell Lung Cancer and Renal Cancer in Combination with Other Treatments
Jul 25, 2012 Agennix AG Schedules Conference Call on July 31 to Discuss Second Quarter 2012 Financial Results
May 09, 2012 Agennix AG Reports Financial Results for First Quarter of 2012
May 04, 2012 Agennix AG to Present at BioEquity Europe 2012 on May 15
May 02, 2012 Agennix AG Schedules Conference Call on May 9 to Discuss First Quarter 2012 Financial Results
Apr 12, 2012 Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Mar 19, 2012 Agennix AG to Participate in 6th Annual International Partnering Conference BIO-Europe Spring® 2012
Mar 16, 2012 Agennix AG to Participate in 5th Kempen & Co Healthcare/Life Sciences Conference
Mar 15, 2012 Agennix AG Reports Financial Results For Fiscal Year 2011
Mar 13, 2012 DSM and Agennix Sign New Contract for Commercial Manufacture of Talactoferrin
Mar 08, 2012 Agennix AG Schedules Conference Call on March 15
Feb 02, 2012 Agennix AG Halts Phase II/III OASIS Trial in Severe Sepsis
Jan 30, 2012 Agennix AG to Present at Three Conferences in February